TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05984797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Short-term Palliative Rehabilitation
Description: Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,).~Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians.
Study: NCT05167812

Intervention type: OTHER
Intervention: Observation of pregnancies after intake
Description: Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss

Intervention type: OTHER
Intervention: Observation of pregnancies after intake
Description: Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
Study: NCT05096013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual nutritional therapy
Description: Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
Study: NCT05994586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP029 mix
Description: Polyphenol-rich plant extracts Twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP029 mix
Description: Polyphenol-rich plant extracts Twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day
Study: NCT05814471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cable fastening system and 3d printed straps
Description: The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
Study: NCT05081596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH-Pain
Description: The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes.
Study: NCT05456698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity.
Study: NCT05814471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Velcro straps system
Description: The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
Study: NCT04904107

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: modified HEART score (including POC hs cTnI analysis)
Description: The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care and triage according to the local (EMT)protocol.
Description: Standard care and triage of chest pain patients according to the local (EMT)protocol.
Study: NCT05979961

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT and concurrent cisplatin
Description: Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT and concurrent cisplatin
Description: Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
Study: NCT05967429

Intervention type: DIAGNOSTIC_TEST
Intervention: The neutrophil-to- lymphocyte ratio
Description: It was calculated by dividing the neutrophil count by the lymphocyte count.

Intervention type: DIAGNOSTIC_TEST
Intervention: Prognostic nutrition index
Description: It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
Study: NCT05979961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin (Induction chemotherapy)
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
Study: NCT05698303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
Description: CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
Study: NCT04645173

Intervention type: DEVICE
Intervention: CIED envelope
Description: Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
Study: NCT06222983

Intervention type: PROCEDURE
Intervention: CEA or CAS
Description: After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness

Intervention type: PROCEDURE
Intervention: CEA or CAS
Description: After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
Study: NCT05958836

Intervention type: DEVICE
Intervention: pacemaker
Description: Micra TPS or traditional PM group
Study: NCT06516328

Intervention type: OTHER
Intervention: Observational
Description: GCF and saliva samples obtained.

Intervention type: OTHER
Intervention: Observational
Description: GCF and saliva samples obtained.

Intervention type: OTHER
Intervention: Observational
Description: GCF and saliva samples obtained.

Intervention type: OTHER
Intervention: Observational
Description: GCF and saliva samples obtained.
Study: NCT05779215

Intervention type: OTHER
Intervention: Visit at D90
Description: Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
Study: NCT06358534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: psychoeducation based on acceptance and commitment therapy prepared by the researchers was applied individually to the patients
Study: NCT04677192

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microwave Ablation combination with chemotherapy
Description: Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
Study: NCT01023152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated cuff-inflator
Description: RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
Study: NCT06307847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP5M001 inj
Description: pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synovian inj
Description: pre-filled syringe
Study: NCT04924621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.
Description: The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mask ventilation
Description: The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam(T group)
Description: Midazolam 0.05mg/kg, intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentani(T group)
Description: Sufentanil 0.02-0.05ug/kg, intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol(T group)
Description: Propofol 2-3ug/ml, intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium(T group)
Description: Rocuronium 0.06mg/kg, intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug use target(T group)
Description: Make BIS \< 60 .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil(C group)
Description: Sufentanil 5ug, intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam(C group)
Description: Midazolam 0.05mg/kg, intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol 1-2ug/ml, intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetracaine(C group)
Description: 2ml tetracaine was injected with cyclothyroid membrane puncture.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug use target
Description: Make the BIS between 70 and 80.
Study: NCT06386172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support trigger
Description: Investigation of CDS-triggers effect on primary care physicians detection and management of chronic kidney disease
Study: NCT04529434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Star Homes
Description: 110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight \& durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional African houses
Description: A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
Study: NCT05684952

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shenlingcao Oral Liquid
Description: Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenlingcao Oral Liquid
Description: Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
Study: NCT04994652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Description: Indirect laryngoscopy using the C-MAC videolaryngoscope
Study: NCT05079126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: Single IV Bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV Bolus
Study: NCT04994652

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Direct laryngoscopy with a standard laryngoscope
Study: NCT06416228

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
Study: NCT05404074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod 500mg
Description: Rectal administration
Study: NCT05886452

Intervention type: DEVICE
Intervention: DT1fA contact lenses
Description: Subjects will be fitted with DT1fA contact lenses
Study: NCT06148064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaplug with low level laser
Description: Immediate implant placement with applying a collaplug material in the jumping gap followed by low level laser application using Siro laser (660 nm, avg. power density: 0.5-WATT) circular spot diameter and area: 0.71 cm/0.4cm2) applied in six points in contact mode with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before bone perforation and after suturing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collaplug
Description: Implant of suitable diameter and height was placed in the fresh extracted socket immediately after extraction and the jumping gap was augmented by the collaplug followed by healing abutment placement.
Study: NCT06416228

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
Study: NCT06160518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
Study: NCT05546307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSEP
Description: Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSEP
Description: Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation session
Description: The relaxation session will be performed by one of the 5 nurses trained in relaxation
Study: NCT04710511

Intervention type: OTHER
Intervention: Child and Youth Resilience Measure - Revised (CYRM-R)
Description: (CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent

Intervention type: OTHER
Intervention: Child and Youth Resilience Measure - Revised (CYRM-R)
Description: (CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
Study: NCT04979286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Kinesiotaping
Description: Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
Study: NCT05589961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
Study: NCT05579574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: Specified dose on specified days
Study: NCT04973553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper limb rehabilitation
Description: the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
Study: NCT06186492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-006
Description: RNA editing oligonucleotide
Study: NCT06518538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613, modified Folfirinox
Description: * CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan
Study: NCT05979233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: staged managment
Description: staged management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one session ERCP then LC
Description: one session ERCP then LC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one session LC then ERCP
Description: one session LC then ERCP
Study: NCT05521464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cast
Description: Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robert Jones Bandage
Description: Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
Study: NCT06285968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Sleep Health Promotion Intervention
Description: Multi-component multidimensional sleep health promotion intervention that includes sleep health and sleep hygiene education, behavioral coaching, personalized feedback, goal setting and establishment of a sleep health plan, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.
Study: NCT04231734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
Study: NCT05994820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy Baby Programme -Vaccine Campaign
Description: The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy Baby Programme- Vaccine ++ Campaign
Description: The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.